TY - JOUR
T1 - Probiotics administration following sleeve gastrectomy surgery
T2 - A randomized double-blind trial
AU - Sherf-Dagan, S.
AU - Zelber-Sagi, S.
AU - Zilberman-Schapira, G.
AU - Webb, M.
AU - Buch, A.
AU - Keidar, A.
AU - Raziel, A.
AU - Sakran, N.
AU - Goitein, D.
AU - Goldenberg, N.
AU - Mahdi, J. A.
AU - Pevsner-Fischer, M.
AU - Zmora, N.
AU - Dori-Bachash, M.
AU - Segal, E.
AU - Elinav, E.
AU - Shibolet, O.
N1 - Funding Information:
This study was supported (in part) by grant no. 3-10470 from the Chief Scientist Office of the Ministry of Health, Israel. The funding source did not have a role in the design, conduct and analysis of the study or the decision to submit the manuscript for publication.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background:Probiotics are commonly used after bariatric surgery; however, uncertainty remains regarding their efficacy. Our aim was to compare the effect of probiotics vs placebo on hepatic, inflammatory and clinical outcomes following laparoscopic sleeve gastrectomy (LSG).Methods:This randomized, double-blind, placebo-controlled, trial of 6-month treatment with probiotics (Bio-25; Supherb) vs placebo and 6 months of additional follow-up was conducted among 100 morbidly obese nonalcoholic fatty liver disease (NAFLD) patients who underwent LSG surgery. The primary outcome was a reduction in liver fat content, measured by abdominal ultrasound, and secondary outcomes were improvement of fibrosis, measured by shear-wave elastography, metabolic and inflammatory parameters, anthropometrics and quality of life (QOL). Fecal samples were collected and analyzed for microbial composition.Results:One hundred patients (60% women, mean age of 41.9±9.8 years and body mass index of 42.3±4.7 kg m '2) were randomized, 80% attended the 6-month visit and 77% completed the 12-month follow-up. Fat content and NAFLD remission rate were similarly reduced in the probiotics and placebo groups at 6 months postsurgery ('0.9±0.5 vs '0.7±0.4 score; P=0.059 and 52.5 vs 40%; P=0.262, respectively) and at 12 months postsurgery. Fibrosis, liver-enzymes, C-reactive protein (CRP), leptin and cytokeratin-18 levels were significantly reduced and QOL significantly improved within groups (P1/20.014 for all), but not between groups (P3/40.173 for all) at 6 and 12 months postsurgery. Within-sample microbiota diversity (alpha-diversity) increased at 6-month postsurgery compared with baseline in both study arms (P1/20.008) and decreased again at 12 months postsurgery compared with 6 months postsurgery (P1/20.004) but did not reach baseline values.Conclusions:Probiotics administration does not improve hepatic, inflammatory and clinical outcomes 6- and 12 months post-LSG.
AB - Background:Probiotics are commonly used after bariatric surgery; however, uncertainty remains regarding their efficacy. Our aim was to compare the effect of probiotics vs placebo on hepatic, inflammatory and clinical outcomes following laparoscopic sleeve gastrectomy (LSG).Methods:This randomized, double-blind, placebo-controlled, trial of 6-month treatment with probiotics (Bio-25; Supherb) vs placebo and 6 months of additional follow-up was conducted among 100 morbidly obese nonalcoholic fatty liver disease (NAFLD) patients who underwent LSG surgery. The primary outcome was a reduction in liver fat content, measured by abdominal ultrasound, and secondary outcomes were improvement of fibrosis, measured by shear-wave elastography, metabolic and inflammatory parameters, anthropometrics and quality of life (QOL). Fecal samples were collected and analyzed for microbial composition.Results:One hundred patients (60% women, mean age of 41.9±9.8 years and body mass index of 42.3±4.7 kg m '2) were randomized, 80% attended the 6-month visit and 77% completed the 12-month follow-up. Fat content and NAFLD remission rate were similarly reduced in the probiotics and placebo groups at 6 months postsurgery ('0.9±0.5 vs '0.7±0.4 score; P=0.059 and 52.5 vs 40%; P=0.262, respectively) and at 12 months postsurgery. Fibrosis, liver-enzymes, C-reactive protein (CRP), leptin and cytokeratin-18 levels were significantly reduced and QOL significantly improved within groups (P1/20.014 for all), but not between groups (P3/40.173 for all) at 6 and 12 months postsurgery. Within-sample microbiota diversity (alpha-diversity) increased at 6-month postsurgery compared with baseline in both study arms (P1/20.008) and decreased again at 12 months postsurgery compared with 6 months postsurgery (P1/20.004) but did not reach baseline values.Conclusions:Probiotics administration does not improve hepatic, inflammatory and clinical outcomes 6- and 12 months post-LSG.
UR - http://www.scopus.com/inward/record.url?scp=85041652186&partnerID=8YFLogxK
U2 - 10.1038/ijo.2017.210
DO - 10.1038/ijo.2017.210
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 28852205
AN - SCOPUS:85041652186
SN - 0307-0565
VL - 42
SP - 147
EP - 155
JO - International Journal of Obesity
JF - International Journal of Obesity
IS - 2
ER -